Propranolol on Post Stroke Immune Status and Infection
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Stroke-associated pneumonia (SAP) is one of the important risk factors influencing poor
outcomes and death in stroke patients. Over the past two decades, accumulating evidence
suggests that post-stroke brain injury mobilizes the adrenergic system, which induces
post-stroke immunosuppression and SAP. This study is designed to test the safety and efficacy
of an adrenergic β-receptor blocker, propranolol, with or without combination of antibiotics,
in reducing SAP in stroke patients. The underlying immune mechanisms will be investigated.